Clinical Trial Update: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) [Phase 2]

View source ↗

Summary

A Phase II clinical trial is investigating a triplet regimen of zanubrutinib, obinutuzumab, and venetoclax in patients with chronic lymphocytic leukemia or smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | Phase 2 | Status: RECRUITING